NGQ1 Stock Overview
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Medicure Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.73 |
52 Week High | CA$1.16 |
52 Week Low | CA$0.66 |
Beta | 1 |
1 Month Change | -3.95% |
3 Month Change | -3.31% |
1 Year Change | -16.09% |
3 Year Change | -23.16% |
5 Year Change | -81.35% |
Change since IPO | -96.26% |
Recent News & Updates
Recent updates
Shareholder Returns
NGQ1 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -4.9% | -1.5% |
1Y | -16.1% | -19.9% | 0.9% |
Return vs Industry: NGQ1 exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: NGQ1 underperformed the German Market which returned -0.4% over the past year.
Price Volatility
NGQ1 volatility | |
---|---|
NGQ1 Average Weekly Movement | 22.6% |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NGQ1's share price has been volatile over the past 3 months.
Volatility Over Time: NGQ1's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | n/a | Albert Friesen | www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
NGQ1 fundamental statistics | |
---|---|
Market cap | €7.69m |
Earnings (TTM) | -€629.15k |
Revenue (TTM) | €14.80m |
0.5x
P/S Ratio-11.7x
P/E RatioIs NGQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NGQ1 income statement (TTM) | |
---|---|
Revenue | CA$21.69m |
Cost of Revenue | CA$7.71m |
Gross Profit | CA$13.99m |
Other Expenses | CA$14.91m |
Earnings | -CA$922.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.088 |
Gross Margin | 64.48% |
Net Profit Margin | -4.25% |
Debt/Equity Ratio | 0% |
How did NGQ1 perform over the long term?
See historical performance and comparison